{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:58:23Z","timestamp":1791248303972,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s40123-026-01349-6","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T17:09:17Z","timestamp":1773508157000},"page":"1499-1508","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Lower Rates of Intraocular Inflammation with Aflibercept 8\u00a0mg Delivered via Pre-Filled Syringe Versus Vial"],"prefix":"10.1007","volume":"15","author":[{"given":"Laura","family":"Hoffmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2807-0310","authenticated-orcid":false,"given":"Katja","family":"Hatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,14]]},"reference":[{"issue":"14","key":"1349_CR1","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419\u201331.","journal-title":"N Engl J Med"},{"issue":"12","key":"1349_CR2","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537\u201348.","journal-title":"Ophthalmology"},{"issue":"9","key":"1349_CR3","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/jamaophthalmol.2023.2421","volume":"141","author":"CC Wykoff","year":"2023","unstructured":"Wykoff CC, Brown DM, Reed K, et al. Effect of high-dose intravitreal aflibercept, 8 mg, in patients with neovascular age-related macular degeneration. JAMA Ophthalmol. 2023;141(9):834.","journal-title":"JAMA Ophthalmol"},{"issue":"10432","key":"1349_CR4","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/S0140-6736(23)02577-1","volume":"403","author":"DM Brown","year":"2024","unstructured":"Brown DM, Boyer DS, Do DV, et al. Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2\/3 trial. Lancet. 2024;403(10432):1153\u201363.","journal-title":"Lancet"},{"issue":"10432","key":"1349_CR5","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","volume":"403","author":"P Lanzetta","year":"2024","unstructured":"Lanzetta P, Korobelnik JF, Heier JS, et al. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet. 2024;403(10432):1141\u201352.","journal-title":"Lancet"},{"key":"1349_CR6","unstructured":"Garweg J. A pooled analysis of the CANDELA, PHOTON, and PULSAR trials through 96 weeks: Comparably low intraocular inflammation (IOI)-related events with aflibercept 8 mg and 2 mg. In: ARVO Annual Meeting Abstract. Invest Ophthalmol & Visual Sci; 2025."},{"key":"1349_CR7","doi-asserted-by":"crossref","unstructured":"Sisk RA. Occlusive Retinal Vasculitis After Aflibercept 8mg Injection for Wet Macular Degeneration. Retin Cases Brief Rep. 2025.","DOI":"10.1097\/ICB.0000000000001757"},{"issue":"6","key":"1349_CR8","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1001\/jamaophthalmol.2025.0969","volume":"143","author":"KE Binder","year":"2025","unstructured":"Binder KE, Bleidi\u00dfel N, CharbelIssa P, Maier M, Coulibaly LM. Noninfectious intraocular inflammation after intravitreal aflibercept. JAMA Ophthalmol. 2025;143(6):499.","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"1349_CR9","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1186\/s12886-024-03788-w","volume":"24","author":"L Hoffmann","year":"2024","unstructured":"Hoffmann L, Michels S, Eandi C, Al KM, de Figueiredo EC, O, Hatz K. Aflibercept high-dose (8mg) related intraocular inflammation (IOI) \u2013 a case series. BMC Ophthalmol. 2024;24(1):520.","journal-title":"BMC Ophthalmol"},{"issue":"5","key":"1349_CR10","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s10384-024-01107-w","volume":"68","author":"H Matsumoto","year":"2024","unstructured":"Matsumoto H, Hoshino J, Numaga S, Mimura K, Asatori Y, Akiyama H. Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degeneration. Jpn J Ophthalmol. 2024;68(5):531\u20137.","journal-title":"Jpn J Ophthalmol"},{"issue":"1","key":"1349_CR11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40942-021-00307-7","volume":"7","author":"WJ Anderson","year":"2021","unstructured":"Anderson WJ, da Cruz NFS, Lima LH, Emerson GG, Rodrigues EB, Melo GB. Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review. Int J Retina Vitreous. 2021;7(1):37.","journal-title":"Int J Retina Vitreous"},{"issue":"23","key":"1349_CR12","doi-asserted-by":"publisher","first-page":"7401","DOI":"10.3390\/jcm12237401","volume":"12","author":"H Matsubara","year":"2023","unstructured":"Matsubara H, Nagashima R, Chujo S, et al. Subclinical ocular changes after intravitreal injections of different anti-VEGF agents for neovascular age-related macular degeneration. J Clin Med. 2023;12(23):7401.","journal-title":"J Clin Med"},{"issue":"4","key":"1349_CR13","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.ajo.2014.06.019","volume":"158","author":"RA Goldberg","year":"2014","unstructured":"Goldberg RA, Shah CP, Wiegand TW, Heier JS. Noninfectious inflammation after intravitreal injection of aflibercept: clinical characteristics and visual outcomes. Am J Ophthalmol. 2014;158(4):733-737.e1.","journal-title":"Am J Ophthalmol"},{"key":"1349_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/943409","volume":"2013","author":"S Agrawal","year":"2013","unstructured":"Agrawal S, Joshi M, Christoforidis JB. Vitreous inflammation associated with intravitreal anti-VEGF pharmacotherapy. Mediators Inflamm. 2013;2013:1\u20136.","journal-title":"Mediators Inflamm"},{"issue":"4","key":"1349_CR15","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1001\/jamaophthalmol.2024.0530","volume":"142","author":"L Thangamathesvaran","year":"2024","unstructured":"Thangamathesvaran L, Kong J, Bressler SB, et al. Severe intraocular inflammation following intravitreal faricimab. JAMA Ophthalmol. 2024;142(4):365.","journal-title":"JAMA Ophthalmol"},{"issue":"5","key":"1349_CR16","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1097\/IAE.0000000000000801","volume":"36","author":"PD Williams","year":"2016","unstructured":"Williams PD, Chong D, Fuller T, Callanan D. Noninfectious vitritis after intravitreal injection of anti-vegf agents. Retina. 2016;36(5):909\u201313.","journal-title":"Retina"},{"issue":"9","key":"1349_CR17","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1097\/IAE.0b013e3181dc04da","volume":"30","author":"DY Chong","year":"2010","unstructured":"Chong DY, Anand R, Williams PD, Qureshi JA, Callanan DG. Characterization of sterile intraocular inflammatory responses after intravitreal bevacizumab injection. Retina. 2010;30(9):1432\u201340.","journal-title":"Retina."},{"issue":"4","key":"1349_CR18","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1001\/jamaophthalmol.2014.5650","volume":"133","author":"P Hahn","year":"2015","unstructured":"Hahn P, Chung MM, Flynn HW, et al. Postmarketing analysis of aflibercept-related sterile intraocular inflammation. JAMA Ophthalmol. 2015;133(4):421.","journal-title":"JAMA Ophthalmol"},{"issue":"5","key":"1349_CR19","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.ophtha.2012.11.018","volume":"120","author":"P Hahn","year":"2013","unstructured":"Hahn P, Kim JE, Stinnett S, et al. Aflibercept-related sterile inflammation. Ophthalmology. 2013;120(5):1100-1101.e5.","journal-title":"Ophthalmology"},{"issue":"9","key":"1349_CR20","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.oret.2019.04.006","volume":"3","author":"JP Greenberg","year":"2019","unstructured":"Greenberg JP, Belin P, Butler J, et al. Aflibercept-related sterile intraocular inflammation outcomes. Ophthalmol Retina. 2019;3(9):753\u20139.","journal-title":"Ophthalmol Retina"},{"issue":"10","key":"1349_CR21","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.ophtha.2020.04.017","volume":"127","author":"CR Baumal","year":"2020","unstructured":"Baumal CR, Spaide RF, Vajzovic L, et al. Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab. Ophthalmology. 2020;127(10):1345\u201359.","journal-title":"Ophthalmology"},{"issue":"7","key":"1349_CR22","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.ophtha.2020.11.011","volume":"128","author":"J Mon\u00e9s","year":"2021","unstructured":"Mon\u00e9s J, Srivastava SK, Jaffe GJ, et al. Risk of inflammation, retinal vasculitis, and retinal occlusion\u2013related events with brolucizumab. Ophthalmology. 2021;128(7):1050\u20139.","journal-title":"Ophthalmology"},{"issue":"10","key":"1349_CR23","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1097\/IAE.0000000000003862","volume":"43","author":"P Pakravan","year":"2023","unstructured":"Pakravan P, Patel V, Lai J, et al. Intraocular inflammation incidence after intravitreal brolucizumab injection for exudative age-related macular degeneration. Retina. 2023;43(10):1717\u201322.","journal-title":"Retina."},{"issue":"4","key":"1349_CR24","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2174\/1389201023378175","volume":"3","author":"E Koren","year":"2002","unstructured":"Koren E, Zuckerman L, Mire-Sluis A. Immune responses to therapeutic proteins in humans - clinical significance, assessment and prediction. Curr Pharm Biotechnol. 2002;3(4):349\u201360.","journal-title":"Curr Pharm Biotechnol"},{"key":"1349_CR25","doi-asserted-by":"crossref","unstructured":"Stoehr LN, Wakili P, Darwisch W, et al. Intraocular inflammation following aflibercept 8\u00a0mg: real-world data from a multicentre retrospective observational study. Int J Retina Vitreous. 2025.","DOI":"10.21203\/rs.3.rs-7714357\/v1"},{"issue":"3","key":"1349_CR26","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","volume":"140","author":"Standardization of Uveitis Nomenclature for Reporting Clinical Data","year":"2005","unstructured":"Standardization of Uveitis Nomenclature for Reporting Clinical Data. Results of the First International Workshop. Am J Ophthalmol. 2005;140(3):509\u201316.","journal-title":"Am J Ophthalmol"},{"key":"1349_CR27","unstructured":"Bayer AG LG. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/eylea-epar-product-information_en.pdf. 2025."},{"issue":"4","key":"1349_CR28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1167\/iovs.65.4.10","volume":"65","author":"A Mart\u00ednez-Vacas","year":"2024","unstructured":"Mart\u00ednez-Vacas A, Di Pierdomenico J, G\u00f3mez-Ramirez AM, Vidal-Sanz M, Villegas-P\u00e9rez MP, Garc\u00eda-Ayuso D. Dose-related side effects of intravitreal injections of humanized anti-vascular endothelial growth factor in rats: glial cell reactivity and retinal ganglion cell loss. Invest Opthalmol & Vis Sci. 2024;65(4):10.","journal-title":"Invest Opthalmol & Vis Sci"},{"key":"1349_CR29","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.2147\/OPTH.S199771","volume":"13","author":"R Filek","year":"2019","unstructured":"Filek R, Hooper P, Sheidow T, Liu H, Chakrabarti S, Hutnik CM. Safety of anti-VEGF treatments in a diabetic rat model and retinal cell culture. Clin Ophthalmol. 2019;13:1097\u2013114.","journal-title":"Clin Ophthalmol"},{"issue":"10","key":"1349_CR30","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1080\/17425255.2024.2401600","volume":"20","author":"MW Stewart","year":"2024","unstructured":"Stewart MW. Intraocular drugs: pharmacokinetic strategies and the influence on efficacy and durability. Expert Opin Drug Metab Toxicol. 2024;20(10):977\u201387.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1349_CR31","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2147\/OPTH.S393519","volume":"17","author":"U Schmidt-Ott","year":"2023","unstructured":"Schmidt-Ott U, Fitzpatrick S, Hasanbasic Z, et al. Reported rates of intraocular inflammation with intravitreal aflibercept administered via pre-filled syringe or from vials in clinical practice between 2012 and 2022. Clin Ophthalmol. 2023;17:385\u201390.","journal-title":"Clin Ophthalmol"},{"issue":"5","key":"1349_CR32","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1097\/IAE.0000000000004394","volume":"45","author":"A Montesel","year":"2025","unstructured":"Montesel A, Sen S, Preston E, et al. Intraocular inflammation associated with faricimab therapy. Retina. 2025;45(5):827\u201332.","journal-title":"Retina"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01349-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01349-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01349-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T12:42:35Z","timestamp":1775133755000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-026-01349-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,14]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1349"],"URL":"https:\/\/doi.org\/10.1007\/s40123-026-01349-6","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,14]]},"assertion":[{"value":"8 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Laura Hoffmann received travel grants from Bayer and Roche. Katja Hatz received fees for consultancies and advisory board participation from Novartis, Bayer, Roche, Allergan\/AbbVie.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Approval to conduct this study was obtained from the local ethics committee Ethikkommission Nordwestschweiz (EKNZ; BASEC No 2025\u201301725). The study was conducted according to the Tenets of the Declaration of Helsinki. Since the study represents a safety analysis, all intravitreal injections were included. Individual patient consent was given through our general consent form for subjects explicitly mentioned in the figures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}